Genprex Inc
For the period ended Dec 31, 2023. Filed Apr 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 1, 2024
GNPX$2.06-0.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
| Year Ended | ||
|---|---|---|
| December 31, | ||
| 2023 | 2022 | |
| Cash flows from operating activities: | ||
| Net loss | $(30,860,461) | $(23,740,621) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 15,004 | 25,575 |
| Share-based compensation | 5,408,728 | 4,731,944 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 34,852 | (34,852) |
| Prepaid expenses and other | (309,914) | 27,125 |
| Research and development supplies | 517,449 | 157,465 |
| Deposits | 11,818 | (13,127) |
| Accounts payable | 954,686 | (530,269) |
| Other current liabilities | (510,765) | 1,755,262 |
| Net cash used in operating activities | (24,738,603) | (17,621,498) |
| Cash flows from investing activities: | ||
| Reductions to property and equipment | 169 | — |
| Additions to intellectual property | (71,383) | (59,735) |
| Net cash used in investing activities | (71,214) | (59,735) |
| Cash flows from financing activities: | ||
| Net proceeds from issuances of common stock | 10,593,377 | 6,426 |
| Net cash provided by financing activities | 10,593,377 | 6,426 |
| Net decrease in cash | (14,216,440) | (17,674,807) |
| Cash and cash equivalents, beginning of year | 20,954,069 | 38,628,876 |
| Cash and cash equivalents, end of year | $6,737,629 | $20,954,069 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.